glp-1 oral receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Oral GLP-1s rapidly expanding user

discussion 209215

Nutrients, 16 (20), 3545

These findings shed light on mechanisms underlying 5FU resistance and propose a rational strategy for combination therapy in CRC, emphasizing the potential clinical benefit of targeting mitochondrial metabolism to overcome resistance and enhance patient outcomes

This decline contributes to multiple hallmarks of aging including decreased muscle mass and strength, increased fat accumulation, reduced bone density, impaired cognitive function, and compromised immune system performance

Safety and tolerability issues were also similar across groups, suggesting that dose adjustment is not required in patients with hepatic impairment

Conclusion In conclusion, our study suggests that acyl-carnitines provide a potential pathway in the pathoetiology of schizophrenia